Eurocine Vaccines expands its portfolio with a therapeutic HSV-2 vaccine candidate
Eurocine Vaccines AB ("Eurocine Vaccines") hereby announces that the company has entered into a research and collaboration agreement with Redbiotec AG ("Redbiotec"). The agreement gives…
Eurocine Vaccines publishes interim report for July 2021 – March 2022
Eurocine Vaccines AB (publ) (”Eurocine Vaccines) hereby publishes the interim report for July 2021 to December 2022. Below is a summary of the report. The…
Eurocine Vaccines publishes CEO interview
CEO Hans Arwidsson discussed the vaccine portfolio, the progress with the chlamydia vaccine candidate, and the future plans for the business in an interview conducted…
Eurocine Vaccines publishes half-year report for July – December 2021
Eurocine Vaccines AB (“Eurocine Vaccines”) hereby publishes the half-year report for July to December 2021. Below is a summary of the report. The full report…
Eurocine Vaccines enters into agreement with Flerie Invest to secure exercise of warrants of series TO 4
Eurocine Vaccines AB (“Eurocine Vaccines” or “the Company”) announces today that the Company has agreed to secure warrants of series TO 4 (“TO 4”) with…
Eurocine Vaccines resolves on scientific advice with the Swedish Medical Products Agency ahead of clinical trial application
The Board of Directors of Eurocine Vaccines has resolved to request scientific advice from the Swedish Medical Products Agency ahead of submitting the clinical trial…
Eurocine Vaccines´ Chlamydia vaccine candidate elicits both antibody and T cell responses
In the latest preclinical study, it was shown that intramuscular immunization with the Chlamydia vaccine candidate elicits an excellent T cell response, in addition to…
Correction: Eurocine Vaccines discloses interim report for July – September 2021
Correction: In the interim report for July – September 2021, information whether the report has been reviewed by the company’s auditor was not included. The…
Eurocine Vaccines discloses interim report for July – September 2021
Eurocine Vaccines AB hereby discloses the interim report for July – September 2021. Below is a summary of the report. The full report is available…
Disclosure notice in Eurocine Vaccines
Eurocine Vaccines hereby announces that Flerie Invest AB has acquired shares in the company and holds above 10 % of the shares in the company.…